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Abstract
Background: Esophagectomy or pancreaticoduodenecto-
my is the standard surgical approach for patients with tu-
mors of the esophagus or pancreatic head. Postoperative 
mortality is strongly correlated with the occurrence of anas-
tomotic leakage (AL). Delay in diagnosis leads to delay in 
treatment, which ratifies the need for development of novel 
and accurate non-invasive diagnostic tests for detection of 
AL. Urinary volatile organic compounds (VOCs) reflect the 
metabolic status of an individual, which is associated with a 
systemic immunological response. The aim of this study was 
to determine the diagnostic accuracy of urinary VOCs to de-
tect AL after esophagectomy or pancreaticoduodenectomy. 
Methods: In the present study, urinary VOCs of 63 patients 
after esophagectomy (n = 31) or pancreaticoduodenectomy 
(n = 32) were analyzed by means of field asymmetric ion mo-
bility spectrometry. AL was defined according to interna-
tional study groups. Results: AL was observed in 15 patients 
(24%). Urinary VOCs of patients with AL after pancreatico-
duodenectomy could be distinguished from uncomplicated 
controls, area under the curve 0.85 (95% CI 0.76–0.93), sen-
sitivity 76%, and specificity 77%. However, this was not ob-
served following esophagectomy, area under the curve 0.51 
(95% CI 0.37–0.65). Conclusion: In our study population AL 
following pancreaticoduodenectomy could be discriminat-
ed from uncomplicated controls by means of urinary VOC 
analysis, NTC03203434. © 2018 The Author(s)  
Published by S. Karger AG, Basel
Introduction 
Anastomotic leakage (AL) is the most dreaded and fre-
quent complication after intestinal surgery, leading to 
significantly increased morbidity and 30-day mortality 
[1]. According to the Dutch Institute for Clinical Audit-
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ing, leakage occurs in 12.8% of pancreaticoduodenecto-
mies and 20% of esophagectomies carried out in the 
Netherlands [2]. 
In current practice, AL is diagnosed based on clinical, 
biochemical, and radiological findings. In the early post-
operative phase, clinical parameters have been shown to 
be indecisive, requiring additional examination [3]. Pri-
mary biochemical predictor is the acute phase C-reactive 
protein (CRP). However, serum CRP lacks sensitivity and 
specificity for major infectious complications [4]. In ad-
dition, increased levels of amylase in drain fluid have been 
shown to be predictive for esophageal [5] and pancreatic 
AL [6]. Nevertheless, early drain removal is favorable for 
the postoperative recovery, preventing secondary infec-
tion and theoretically pancreatitis [7]. This emphasizes 
the need for the development of novel, non-invasive bio-
markers, with high accuracy for predicting and diagnos-
ing AL during the first postoperative days. 
Since 2000 BC, ancient physicians have been diag-
nosing patients based on their own olfactory system [8]. 
Most gases, either odorous or non-odorous, are com-
posed of volatile organic compounds (VOCs). These 
compounds have several origins: firstly, environmental 
or exogenous; secondly, local symptoms from the 
 primary affected disease site in diseased patients which 
is often inflammation or cancer; and thirdly, the sys-
temic (immunological) response [8]. Assessment of 
VOCs in breath, feces, and urine has led to the identi-
fication of a variety of disease-specific smell prints in, 
for example, pulmonology, oncology, and gastroenter-
ology [9–14]. 
The aim of this study was to determine the diagnostic 
accuracy of analysis of urinary VOCs to detect AL non-
invasively after major gastrointestinal surgery. 
Methods
Study Design and Participants
This study was conducted in accordance with the World Med-
ical Association Declaration of Helsinki. The local institutional 
ethical review board of the VU medical center approved the study 
protocol (2014.543). This project was designed as a single center 
prospective observational cohort study between March 2015 and 
April 2016. Eligible participants were diagnosed with (suspected) 
malignancies of the esophagus, pancreas, distal bile duct, ampulla 
of Vater, or duodenum and were scheduled for surgery (i.e., esoph-
agectomy or pancreaticoduodenectomy). Patients were aged 18–
90 years and had an American Society of Anesthesiologists physi-
cal status of 3 or lower. All participants were capable of under-
standing the study information, and signed written informed 
consent. Patient, surgery, and pathology data were prospectively 
registered.
Procedure
Patients were recruited from the department of surgery of the 
VU University medical center (Amsterdam, The Netherlands). 
They were admitted to the hospital 1 day prior to surgery and re-
ceived standard preoperative treatment according to local proto-
col. Patients diagnosed with esophageal cancer underwent the fol-
lowing procedures: Ivor Lewis, McKeown, or transhiatal esopha-
gectomy. For pancreatic cancer, a pancreaticoduodenectomy was 
performed according to Whipple or with preservation of the gas-
tric pylorus (pylorus-preserving pancreaticoduodenectomy 
[PPPD]). All procedures were performed under standardized an-
tibiotic prophylaxis (cefuroxime/metronidazole). In case of a pan-
creaticoduodenectomy, a prophylactic drain was placed at the pan-
creaticojejunostomy. Postoperatively, all patients were treated ac-
cording to local protocol, which consisted of admittance to the 
intensive care unit, medium care, or general ward. Drains were 
removed when drain amylase content was within normal range on 
or after postoperative day 3. Patients did not receive additional 
antibiotics during the first 3 postoperative days. 
Endpoints
The primary endpoint of this study concerned clinical postop-
erative AL. Leakage following esophageal surgery was defined by the 
Esophagectomy Complications Consensus Group as a full thickness 
defect involving the esophageal anastomosis. Severity was graded 
based on required treatment. Grade 1 was a local defect only requir-
ing medical treatment with dietary modification. Grade 2 required 
interventional but not surgical therapy, and grade 3 AL was surgi-
cally treated [15]. Leakage of the pancreaticojejunostomy was de-
fined as any measurable volume of drain fluid on or after postopera-
tive day 3, with amylase content more than 3 times the upper normal 
serum volume. The International Study Group on Pancreatic Fis-
tula graded leakage according to clinical impact. A biochemical leak 
(formerly grade A) has by definition no clinical impact and was 
therefore not listed as clinical AL. Grade B requires a change in ther-
apeutic management of the expected postoperative pathway. Grade 
C consists of AL-related organ failure or clinical instability such that 
a reoperation was needed [16]. Furthermore, other postoperative 
complications were prospectively registered. For this study, a 30-day 
morbidity was determined and all complications were detected us-
ing local protocol, consisting of daily physical and routine biochem-
ical examinations. When clinical signs were indicative for AL, radio-
logic or endoscopic imaging was requested to objectify.
Sample Collection
Urinary samples were collected in 4.5 mL containers (Cryo-
pure®) on postoperative day 1, 2, and 3. All samples were obtained 
from urinary catheters while maintaining a sterile system. Subse-
quently, samples were frozen at –80  ° C within 2 h of collection for 
simultaneous batch analysis. 
Field Asymmetric Ion Mobility Spectrometry of Urinary Gas
Urinary gas analysis was performed using a commercial field 
asymmetric ion mobility spectrometry (FAIMS) unit (Lonestar, 
Owlstone, UK). FAIMS utilizes high electric fields to separate dif-
ferent ionized chemicals based on their movement (called mobil-
ity) in this high electric field. The unit was fitted with an ATLAS 
sampling system (Owlstone UK), which heats the urine sample to 
38  ° C and controls the flow of clean air over the top of the sample 
and into the Lonestar instrument. The flow rate of the carrier gas 
Non-Invasive Detection of AL 3Dig Surg
DOI: 10.1159/000488007
(dry clean air) over the sample was 500 mL/min, with a total flow 
into the Lonestar of 2 L/min. The inlet of the Lonestar was heated 
to 100  ° C to ensure that no condensation occurred. Inside the unit, 
headspace VOCs are ionized using a NI-63 radiation source and 
passed between 2 parallel plates. Onto these plates a high-electric 
field is applied, which attracts, repels, or does not affect the ions. 
Ions that touch one of the plates lose their charge and are not de-
tected. A compensation voltage is added to one of the plates to 
counteract this movement. By scanning through a range of com-
pensation voltages (+6 to –6 V in 512 steps), a wide range of dif-
ferent mobilities were measured. Furthermore, the magnitude of 
the electric field is scanned through a range of levels (called the 
dispersion field), which was increased in 51 steps. Three scans of 
the compensation voltage and dispersion field strength were per-
formed for each sample. By measuring positive and negative ions, 
a total of 156,672 data points were collected per sample. Further 
details of this analysis have been described previously [17]. 
Analysis
Samples were stored in the freezer for a maximum of 12 months. 
Levels of VOCs start to reduce after 9 months of storage [18]. Sam-
ples were removed from the freezer to defrost at room temperature 
for a maximum of 2 h. Before analysis, the 4.5 mL of sample was 
aliquoted into a 22 mL glass vial, placed in the Lonestar, and heat-
ed to 38  ° C. All samples were measured in triplicate. Before and 
after each urine sample, a sample of clean tap water was run 3 times 
to ensure that the baseline response was returned. Glass vials were 
sanitized at the department of microbiology after each sample. 
Statistical Analysis
Demographic and disease specific data will be tabulated. Uri-
nary VOCs of patients with AL were compared to control patients 
who had an uncomplicated postoperative course for both types of 
surgery. Data of the 3 separate days were combined for both 
groups before comparison. IBM SPSS statistics (version 23) was 
used for standard statistical analysis. All continuous variables are 
expressed as median and range; percentages were calculated for 
dichotomous variables. When appropriate, baseline characteris-
tics were compared with an independent sample t test or Fisher’s 
exact test. The FAIMS dataset was analyzed using our existing 
pipeline developed for previous studies (13). In brief, first a de-
noising step was applied to the FAIMS data, followed by a data 
compression algorithm to reduce the dimensionality of the data. 
Ten-fold cross-validation was then used to assess classifier perfor-
mance. Figure 1 shows urinary VOC data of a patient in the AL 
group and an uncomplicated patient following pancreaticoduode-
nectomy. The displayed samples are closest to the mean for their 
group (AL or uncomplicated) and therefore representative of the 
average result.
Dimensionality reduction was undertaken using a 2D wavelet 
transform (specifically Daubechies D4 wavelets) and any resulting 
variables with zero variance were excluded. A 10-fold cross-vali-
dation was then performed, using 90% of the data as a training set, 
and the remaining 10% as a test set. Within each fold, 64 informa-
tive features were identified using a Wilcoxon rank-sum test on 
the training set. These 64 features were then used to train a ran-
dom forest classifier and predict the probability of AL for the sam-
ples in the test set. A separate initial cross-validation was used for 
model selection, comparing sparse logistic regression, radial SVM, 
linear SVM, and stochastic gradient boosting. All models ex-
cept  linear SVM showed statistically significant predictive ability 
(at a 95% significance level) of AL after pancreaticoduodenectomy 
and of these, random forest was found to produce the best classi-
fication results using area under the receiver operator curve 
 (AUROC) as a metric.
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Fig. 1. Urinary VOC data generated using FAIMS from an AL pa-
tient (a) and an uncomplicated patient (b) following pancreatico-
duodenectomy. FAIMS measures positive and negative ion counts 
at a range of compensation voltages (–6 to +6 V in 512 steps) and 
electric field magnitudes (called the dispersion field, 0–100% in 51 
steps) to generate 52,224 data points per scan. Three scans are per-
formed per sample. This figure shows the negative ion counts for 
the final scan. Distinct plumes in the image correlate to the pres-
ence of distinct VOCs in the sample. VOCs, volatile organic com-
pounds.
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Results
Patient Characteristics
Between March 2015 and April 2016, 66 patients were 
eligible for inclusion. Three patients were excluded due to 
intraoperative findings of irresectable tumors or distant 
metastases. A total of 63 patients were included, undergoing 
esophagectomy (n = 31) or pancreaticoduodenectomy (n = 
32), 14 of whom developed AL (24%) postoperatively. Urine 
samples were collected on the first 3 postoperative days, re-
sulting in a total of 184 samples as 5 samples were lost. 
Esophagectomy
Thirty-one patients undergoing esophagectomy were 
included, 25 men and 6 women had a median age of 
63 years (40–81). Nine patients (29%) developed postop-
erative AL and median time to clinical presentation was 
8 days (interquartile range 17.5). All patients developed 
AL within the postoperative admission, except for 1 de-
layed AL, which was diagnosed upon readmission after 
30 days postoperatively. Grade 1 and 2 were seen in 1 pa-
tient and grade 3 was observed in 7 patients. A total of 89 
urine samples were collected, 3 missing samples in the 
leakage group and 1 missing sample in the uncomplicated 
controls. Further subject characteristics are summarized 
in Table 1. No statistically significant differences were 
present between groups. Urinary VOCs were not able 
to distinguish AL from uncomplicated patients, AUROC 
0.51 (95% CIs 0.37–0.65). Results of the random for-
est  analysis for both types of surgery are displayed in 
 Table 2.
Pancreaticoduodenectomy
A total of 32 patients underwent pancreaticoduode-
nectomy – 23 men and 9 women – who had a median age 
of 66 years with a range of 45–82 years. Postoperative 
leakage of the pancreaticojejunostomy was observed in 6 
patients (19%), consisting of 3 level B and 3 level C AL, 
median time to diagnosis was 5 days (interquartile range 
14.25). In 1 case, a delayed AL was diagnosed upon read-
mission on 30 days after surgery. Leakage of the gastro-
jejunostomy or hepaticojejunostomy was not observed. 
A single sample was not collected in the AL group, result-
ing in a total of 95 urine samples. Characteristics of AL 
patients and uncomplicated patients are depicted in Ta-
ble 3, no statistically significant differences were found 
between groups. Further analysis showed that urinary 
VOCs were able to distinguish AL from uncomplicated 
patients following pancreaticoduodenectomy with a sen-
sitivity of 0.76 (95% CI 0.50–0.93) and specificity of 0.77 
(95% CI 0.66–0.86). The AUROC was 0.85 (95% CI 0.76–
0.93) and is displayed in Figure 2. For each sample, the 
predicted probability of AL was determined. Figure 3 
shows the difference in predictive probability broken 
down by surgery type. The predictive probability was 
Table 1. Summary of demographic and clinical characteristics of 
patients undergoing esophageal surgery
Characteristics AL
(n = 9)
Controls
(n = 22)
Gender 
Male 9 (100) 16 (73)
Female 0 (0) 6 (27)
Age, years 70 (40–81) 61 (46–79)
Missing urine samples 3 (11) 1 (2)
Location of the anastomosis
Cervical 2 (22) 8 (36)
Thoracic 7 (78) 14 (64)
Type of carcinoma
Adenocarcinoma 5 (56) 16 (73)
Squamous cell carcinoma 1 (11) 5 (23)
Other 3 (33) 1 (5)
Location of tumor
Upper third 0 (0) 0 (0)
Middle third 0 (0) 0 (0)
Lower third or gastroesophageal
junction 9 (100) 22 (100)
Neoadjuvant treatment
Chemoradiotherapy 9 (100) 20 (91)
None 0 (0) 2 (9)
Lymph nodes resected 20 (13–32) 19 (6–38)
Radical surgery 9 (100) 21 (95)
Comorbidities
Hypertension 5 (56) 9 (41)
Heart failure 1 (11) 3 (14)
Cardiac arrhythmia 1 (11) 0 (0)
COPD 1 (11) 2 (9)
Diabetes mellitus 0 (0) 4 (18)
Chronic kidney disease 0 (0) 3 (14)
Grading according to ECCG
Grade 1 1 (11)
Grade 2 1 (11)
Grade 3 7 (78)
Other postoperative complications
Respiratory failure 2 (22) 1 (5)
Pneumonia 1 (11) 1 (5)
Atrial fibrillation 1 (11) 2 (9)
Other 3 (33) 3 (14)
Hospital stay, days 31 (18–106) 8 (6–17)
ICU stay, days 19 (6–89) 1 (0–7)
30-Day mortality 0 (0) 0 (0)
Data are n (%) and median (range).
AL, anastomotic leakage; COPD, chronic obstructive pulmo-
nary disease; ECCG, Esophagectomy Complications Consensus 
Group; ICU, intensive care unit.
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broken down by postoperative day following pancreati-
coduodenectomy in Figure 4 and revealed that there does 
not appear to be a tendency for individual postoperative 
day samples to be more associated with AL. Samples col-
lected on postoperative day 3 appeared to be more con-
sistently scored as low risk for AL compared to other 
postoperative days.
Discussion
In the present pilot study, urinary VOCs of patients un-
dergoing pancreaticoduodenectomy could predict AL cor-
rectly at an early stage. Urine samples were collected dur-
ing the first 3 postoperative days, while the median time to 
clinical presentation for pancreatic AL was about 5 days. 
Preclinical detection could enable early intervention (per-
cutaneous drainage or laparotomy), possibly leading to 
better outcome and timely start of adjuvant treatment. The 
results suggest that non-invasive urine analysis by means 
of FAIMS can be of value in the early, preclinical detection 
of AL following pancreatic surgery. However, this was not 
observed in patients undergoing esophagectomy.
This study is the first to our knowledge to use VOC 
analysis to diagnose postoperative AL. Leakage is fre-
quently accompanied by, or the result of, anastomotic 
ischemia. This creates localized biochemical and im-
munological changes. These changes consist of decreas-
ing glucose and pyruvate levels and increasing lactate 
and glycerol levels. Mediastinal microdialysis has been 
shown to be a promising method to detect these bio-
chemical changes before the development of significant 
clinical symptoms [19]. Furthermore, during the in-
flammatory response, other endogenous products are 
produced and present themselves as VOCs. These 
VOCs defuse into the blood, are renally excreted, and 
can be detected in urine samples [20, 21]. In current 
practice, inflammation markers as serum CRP are fre-
quently used to detect AL. Research has shown that 
postoperative CRP levels rise in response to the initial 
surgery and show a physiological peak approximately 
48–72 h postoperatively. This hampers the use of CRP 
in this phase. 
Urinary VOCs of patients following esophagectomy 
could not predict AL. Median time to clinical presentation 
of AL and the leaked content might have been important 
factors why the technique appears to be accurate following 
pancreaticoduodenectomy but not esophagectomy. The 
median time to clinical presentation of esophageal AL was 
8 days, compared to 5 days for pancreatic AL. Therefore, 
the preclinical biochemical and immunological changes 
related to AL were possibly not detectable during the first 
3 postoperative days following esophagectomy. Further-
more, pancreatic AL is associated with leakage of pancre-
atic enzymes. Increased levels of pancreatic enzymes in 
drain fluid have shown to be predictive for pancreatic AL 
(6). These enzymes might have contributed to the accu-
racy of the technique following pancreatic surgery.
In general, 3 analytical methods are used to detect gas 
phase VOCs: gas chromatography combined with mass 
spectrometry (GC-MS), electronic nose devices, and IMS. 
Urinary VOC analysis was performed using FAIMS, 
which has a number of advantages over other techniques. 
GC-MS is considered the primary method to detect indi-
vidual VOCs. However, analysis by means of GC-MS is 
costly and time consuming, making it less feasible for the 
clinical setting. Compared with traditional electronic nos-
es, using an array of nanosensors and pattern recognition, 
FAIMS has the advantage of a higher sensitivity (i.e., parts 
per billion to parts per trillion) and an absence of sensor 
drift over time [22], due to the measurement of physical, 
not chemical, properties of the volatile molecules. 
Table 2. AUC, sensitivities, and specificities of FAIMS technique for distinguishing AL from uncomplicated con-
trols for both types of surgery
Type of surgery AUC (95% CI) Sensitivity (95% CI) Specificity (95% CI)
Pancreaticoduodenectomy 0.85 (0.76–0.93) 0.76 (0.50–0.93) 0.77 (0.66–0.86)
p < 0.00001 p < 0.001 p < 0.001
Esophagectomy 0.51 (0.37–0.65) 0.54 (0.33–0.74) 0.55 (0.42–0.67)
p = 0.88 p = 0.48 p = 0.48
p values are calculated by means of the Mann-Whitney U test for AUC, and with the Fisher’s exact test for 
sensitivity and specificity.
AUC, area under the curve; FAIMS, field asymmetric ion mobility spectrometry; AL, anastomotic leakage. 
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In previous gastrointestinal research, feces and ex-
haled breath have frequently been used for VOC analy-
sis [14, 23]. Metabolites of infectious processes in the 
gastrointestinal tract, such as AL, are discharged in 
 feces. Therefore, it could be hypothesized that the anal-
ysis of fecal VOCs is more appropriate to detect AL 
compared to urine. However, collection of feces was 
considered less feasible, due to possible temporary im-
pairment of bowel motility in patients undergoing 
 major gastrointestinal surgery during the early postop-
erative phase. Furthermore, urine was preferred 
over  exhaled breath, due to the costs and logistical chal-
lenges of collection, storage, and analysis of exhaled 
breath.
The greatest limitation of this explorative study is the 
small sample size. However, despite low numbers and a 
substantial heterogeneity within the study population, 
VOC analysis by FAIMS allowed for discrimination be-
tween AL and uncomplicated patients following pancre-
aticoduodenectomy. Due to the small cohort, it was nec-
essary to pool the data across days for each type of sur-
gery when performing the analysis. Since each patient in 
the study contributed multiple urine samples, and all 
samples from a given patient have the same AL status, 
this introduces a potential bias to the results: if the train-
ing data contains samples 1 and 2 from patient A, and 
the test data contains sample 3 from patient A, then 
there is a danger that instead of detecting a VOC signa-
ture for AL, a VOC signature for each patient is detect-
ed and that signature is used to assign AL status to the 
samples in the test data. However, if this effect were 
causing erroneous positive results a positive result would 
have been seen for both the esophageal and pancreatic 
cohorts. Since a positive result was only observed for the 
pancreatic cohort, it can be inferred that the bias intro-
duced by this method is not sufficient to invalidate the 
positive result observed. Furthermore, the small sample 
size prevented us from assessing the potential influence 
of comorbidities, other postoperative complications, 
Table 3. Summary of demographic and clinical characteristics of 
patients undergoing pancreatic surgery
Characteristics AL
(n = 6)
Controls
(n = 26)
Gender
Male 5 (83) 18 (69)
Female 1 (17) 8 (31)
Age, years 69 (58–78) 68 (45–82)
Missing urine samples 1 (6) 0 (0)
Type of resection
Pancreaticoduodenectomy 3 (50) 20 (77)
PPPD 3 (50) 6 (23)
Primary tumor
Pancreas 3 (50) 14 (54)
Ampulla of Vater 1 (17) 4 (15)
Duodenum 1 (17) 2 (8)
Biliary 0 (0) 5 (19)
No malignancy 1 (17) 1 (4)
Lymph nodes resected 7 (4–14) 10 (3–26)
Radical surgery 4 (67) 14 (54)
Comorbidities
Hypertension 3 (50) 15 (58)
Heart failure 1 (17) 2 (8)
Cardiac arrhythmia 0 (0) 4 (15)
COPD 0 (0) 4 (15)
Diabetes mellitus 1 (17) 6 (23)
Chronic kidney disease 0 (0) 0 (0)
Grading according to ISGPF
Grade A 0 (0)
Grade B 1 (17)
Grade C 5 (83)
Other postoperative complications
Gastroparesis 2 (33) 3 (12)
Chyle leakage 1 (17) 4 (15)
Postoperative hemorrhage 1 (17) 2 (8)
Pneumonia 1 (17) 1 (4)
Other 2 (33) 7 (27)
Hospital stay, days 48 (10–95) 11 (4–38)
ICU stay, days 4 (1–88) 0 (0–11)
30-Day mortality 0 (0) 0 (0)
Data are n (%) and median (range).
AL, anastomotic leakage; PPPD, pylorus-preserving pancreati-
coduodenectomy; COPD, chronic obstructive pulmonary disease; 
ISGPF, International Study Group on Pancreatic Fistula; ICU, in-
tensive care unit.
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varying disease stages, and types of cancer requiring 
neo-adjuvant chemotherapy or chemoradiotherapy. 
Further research is justified to address these limitations 
and should focus on improving the accuracy of FAIMS 
and use other analytical methods, such as GC-MS to 
identify individual VOC. 
In conclusion, in our study population, urinary VOC 
analysis allowed for discrimination between AL and 
controls following pancreaticoduodenectomy on all 
3  postoperative days combined. VOC analysis could 
not distinguish AL from controls following esophagec-
tomy.
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